HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ENG
endoglin
Chromosome 9 · 9q34.11
NCBI Gene: 2022Ensembl: ENSG00000106991.15HGNC: HGNC:3349UniProt: B7Z6Y5
533PubMed Papers
21Diseases
1Drugs
626Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
glycosaminoglycan bindingcoreceptor activityregulation of DNA-templated transcriptiontransforming growth factor beta receptor signaling pathwaytelangiectasia, hereditary hemorrhagic, type 1hereditary hemorrhagic telangiectasiavascular diseasearteriovenous hemangioma/malformation
✦AI Summary

Endoglin (ENG) is a vascular endothelium glycoprotein essential for angiogenesis and vascular integrity. ENG functions as a TGF-β coreceptor, regulating the TGF-β/BMP signaling cascade that activates SMAD transcription factors 123. Specifically, ENG is required for GDF2/BMP9 signaling through SMAD1 and modulates TGFB1 signaling through SMAD3 in endothelial cells 13. Beyond angiogenesis, ENG regulates vascular endothelial cell migration and may control endothelial cell shape changes in response to blood flow, driving vascular remodeling and morphology establishment 4. ENG is critical for normal adult vasculature structure and integrity 5. Clinically, ENG mutations cause hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vascular dysplasia characterized by telangiectases and arteriovenous malformations 67. ENG variants account for approximately 44% of HHT cases meeting Curaçao diagnostic criteria 8. ENG mutations also associate with pulmonary arterial hypertension severity, with pathogenic mutations correlating with earlier disease onset 9. Additionally, elevated endothelium-derived ENG delivered via extracellular vesicles triggers astrocyte reactivity and neuroinflammation in Alzheimer's disease pathogenesis 10. ENG's selective expression on tumor vasculature makes it an attractive target for vascular-targeting antiangiogenic cancer therapy 11.

Sources cited
1
Beyond angiogenesis, ENG regulates vascular endothelial cell migration and may control endothelial cell shape changes in response to blood flow, driving vascular remodeling and morphology establishment .
PMID: 17540773
2
ENG is critical for normal adult vasculature structure and integrity .
PMID: 7894484
3
ENG variants account for approximately 44% of HHT cases meeting Curaçao diagnostic criteria .
PMID: 32300199
4
ENG mutations also associate with pulmonary arterial hypertension severity, with pathogenic mutations correlating with earlier disease onset .
PMID: 27260700
5
Additionally, elevated endothelium-derived ENG delivered via extracellular vesicles triggers astrocyte reactivity and neuroinflammation in Alzheimer's disease pathogenesis .
PMID: 40702549
6
ENG's selective expression on tumor vasculature makes it an attractive target for vascular-targeting antiangiogenic cancer therapy .
PMID: 21034418
Disease Associationsⓘ21
telangiectasia, hereditary hemorrhagic, type 1Open Targets
0.86Strong
hereditary hemorrhagic telangiectasiaOpen Targets
0.74Strong
vascular diseaseOpen Targets
0.60Moderate
arteriovenous hemangioma/malformationOpen Targets
0.59Moderate
capillary disorderOpen Targets
0.58Moderate
capillary malformationOpen Targets
0.57Moderate
Abnormality of the cardiovascular systemOpen Targets
0.56Moderate
Abnormality of the vasculatureOpen Targets
0.55Moderate
Abnormal cardiovascular system morphologyOpen Targets
0.55Moderate
congenital anomaly of cardiovascular systemOpen Targets
0.55Moderate
congenital vascular malformationOpen Targets
0.53Moderate
respiratory system diseaseOpen Targets
0.52Moderate
heritable pulmonary arterial hypertensionOpen Targets
0.47Moderate
pulmonary hypertension, primary, 1Open Targets
0.46Moderate
Pulmonary arteriovenous malformationOpen Targets
0.46Moderate
Cerebral arteriovenous malformationOpen Targets
0.46Moderate
Palate telangiectasiaOpen Targets
0.45Moderate
pulmonary arterial hypertensionOpen Targets
0.44Moderate
epistaxisOpen Targets
0.40Moderate
arteriovenous malformations of the brainOpen Targets
0.37Weak
Telangiectasia, hereditary hemorrhagic, 1UniProt
Pathogenic Variants626
NM_001114753.3(ENG):c.1145G>A (p.Cys382Tyr)Pathogenic
not provided|Hereditary hemorrhagic telangiectasia|Cardiovascular phenotype|Telangiectasia, hereditary hemorrhagic, type 1
★★★☆2025→ Residue 382
NM_001114753.3(ENG):c.1517T>A (p.Leu506His)Likely pathogenic
Hereditary hemorrhagic telangiectasia|ENG-related disorder|Telangiectasia, hereditary hemorrhagic, type 1|not provided
★★★☆2025→ Residue 506
NM_001114753.3(ENG):c.1807G>A (p.Gly603Arg)Likely pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|Cardiovascular phenotype|Hereditary hemorrhagic telangiectasia
★★★☆2024→ Residue 603
NM_001114753.3(ENG):c.1268A>G (p.Asn423Ser)Likely pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|not provided|not specified|ENG-related disorder|Cardiovascular phenotype|Hereditary hemorrhagic telangiectasia
★★★☆2024→ Residue 423
NM_001114753.3(ENG):c.1319T>G (p.Val440Gly)Likely pathogenic
Hereditary hemorrhagic telangiectasia|Telangiectasia, hereditary hemorrhagic, type 1|Cardiovascular phenotype|not provided
★★★☆2024→ Residue 440
NM_001114753.3(ENG):c.1586G>A (p.Arg529His)Pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|not provided|Hereditary hemorrhagic telangiectasia|Cardiovascular phenotype|ENG-related disorder
★★★☆2024→ Residue 529
NM_001114753.3(ENG):c.1645T>G (p.Cys549Gly)Likely pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|Hereditary hemorrhagic telangiectasia
★★★☆2024→ Residue 549
NM_001114753.3(ENG):c.1701del (p.Val568fs)Pathogenic
not provided|Telangiectasia, hereditary hemorrhagic, type 1
★★★☆2024→ Residue 568
NM_001114753.3(ENG):c.662T>C (p.Leu221Pro)Likely pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|Hereditary hemorrhagic telangiectasia|not provided|Cardiovascular phenotype|ENG-related disorder
★★★☆2024→ Residue 221
NM_001114753.3(ENG):c.991G>A (p.Gly331Ser)Pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|Hereditary hemorrhagic telangiectasia|not provided|Cardiovascular phenotype
★★★☆2024→ Residue 331
NM_001114753.3(ENG):c.447G>C (p.Trp149Cys)Pathogenic
Hereditary hemorrhagic telangiectasia|not provided|See cases|Cardiovascular phenotype|ENG-related disorder|Telangiectasia, hereditary hemorrhagic, type 1
★★★☆2024→ Residue 149
NM_001114753.3(ENG):c.2T>G (p.Met1Arg)Pathogenic
not provided|Hereditary hemorrhagic telangiectasia|Telangiectasia, hereditary hemorrhagic, type 1
★★★☆2024→ Residue 1
NM_001114753.3(ENG):c.-127C>TPathogenic
Hereditary hemorrhagic telangiectasia|not provided|Telangiectasia, hereditary hemorrhagic, type 1|Cardiovascular phenotype
★★☆☆2026
NM_001114753.3(ENG):c.67+1G>APathogenic
Telangiectasia, hereditary hemorrhagic, type 1|not provided|Hereditary hemorrhagic telangiectasia|Cardiovascular phenotype
★★☆☆2026
NM_001114753.3(ENG):c.1273-2A>GPathogenic
Haemorrhagic telangiectasia 1|not provided|not specified|Telangiectasia, hereditary hemorrhagic, type 1|Hereditary hemorrhagic telangiectasia|Cardiovascular phenotype
★★☆☆2026
NM_001114753.3(ENG):c.1833G>A (p.Trp611Ter)Pathogenic
not provided|Hereditary hemorrhagic telangiectasia|Telangiectasia, hereditary hemorrhagic, type 1
★★☆☆2026→ Residue 611
NM_001114753.3(ENG):c.35_45del (p.Leu12fs)Pathogenic
Telangiectasia, hereditary hemorrhagic, type 1|Hereditary hemorrhagic telangiectasia
★★☆☆2026→ Residue 12
NM_001114753.3(ENG):c.765del (p.Tyr258fs)Pathogenic
not specified|Hereditary hemorrhagic telangiectasia|Telangiectasia, hereditary hemorrhagic, type 1
★★☆☆2026→ Residue 258
NM_001114753.3(ENG):c.659T>C (p.Ile220Thr)Pathogenic
Hereditary hemorrhagic telangiectasia|Telangiectasia, hereditary hemorrhagic, type 1|Cardiovascular phenotype
★★☆☆2026→ Residue 220
NM_001114753.3(ENG):c.816G>A (p.Trp272Ter)Pathogenic
not provided|Cardiovascular phenotype|Hereditary hemorrhagic telangiectasia
★★☆☆2026→ Residue 272
View on ClinVar ↗
Drug Targets1
CAROTUXIMABPhase III
Endoglin inhibitor
angiosarcoma
Related Genes
TGFBR1Protein interaction100%ACVR2AProtein interaction100%BMPR2Protein interaction100%CD19Protein interaction100%TGFB1Protein interaction100%TGFB3Protein interaction99%
Tissue Expression6 tissues
Lung
100%
Ovary
91%
Heart
66%
Liver
24%
Bone Marrow
12%
Brain
8%
Gene Interaction Network
Click a node to explore
ENGTGFBR1ACVR2ABMPR2CD19TGFB1TGFB3
PROTEIN STRUCTURE
Preparing viewer…
PDB5I04 · 2.42 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.37Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.25 [0.17–0.37]
RankingsWhere ENG stands among ~20K protein-coding genes
  • #474of 20,598
    Most Researched533 · top 5%
  • #80of 5,498
    Most Pathogenic Variants626 · top 5%
  • #1,756of 17,882
    Most Constrained (LOEUF)0.37 · top 10%
Genes detectedENG
Sources retrieved50 papers
Response time—
📄 Sources
50▼
1
Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.
PMID: 32573726
Blood · 2020
1.00
2
Endoglin-targeted cancer therapy.
PMID: 21034418
Curr Drug Deliv · 2011
0.90
3
Knee Flexion-Assisted Method for Human-Exoskeleton System.
PMID: 37339043
IEEE Trans Neural Syst Rehabil Eng · 2023
0.84
4
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
PMID: 32300199
Genet Med · 2020
0.80
5
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas.
PMID: 40748238
Cancer Immunol Res · 2025
0.78